J B Chemicals & Pharmaceuticals Ltd

J B Chemicals & Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

J B Chemicals & Pharmaceuticals Ltd

₹ 2,193 0.63%
22 May - close price
jbpharma.com BSE: 506943 NSE: JBCHEPHARM
About

J.B. Chemicals and Pharmaceuticals Limited, established in 1976, is one of India's leading pharmaceutical companies. An integrated, publicly-listed organization with a focus on supplying affordable, quality products both in India and internationally, JBCPL is trusted by healthcare professionals globally. [1]

Key Points

Revenue Split H1FY24
Domestic Formulations - 55%
Export Formulations - 30%
Contract Manufacturing - 13%
APIs - 2% [1]

Website BSE NSE
  • Market Cap ₹ 35,204 Cr.
  • Current Price ₹ 2,193
  • High / Low ₹ 2,225 / 1,603
  • Stock P/E 50.7
  • Book Value ₹ 251
  • Dividend Yield 0.71 %
  • ROCE 25.2 %
  • ROE 18.7 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 31.4%
  • Promoter holding has increased by 1.25% over last quarter.

Cons

  • Stock is trading at 8.72 times its book value
  • Promoter holding has decreased over last 3 years: -5.13%
  • Working capital days have increased from 108 days to 197 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty Pharma Nifty500 Shariah

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
699 853 837 800 809 952 956 914 901 1,040 1,023 991 836
538 618 602 585 614 679 688 668 670 747 724 721 642
Operating Profit 161 235 235 215 195 273 268 245 231 293 298 270 195
OPM % 23% 28% 28% 27% 24% 29% 28% 27% 26% 28% 29% 27% 23%
3 5 7 7 16 5 9 7 14 14 14 17 -17
Interest 12 11 9 12 8 4 2 2 1 1 1 2 1
Depreciation 31 31 32 33 40 40 41 41 44 41 43 44 49
Profit before tax 122 198 201 176 163 234 234 210 199 265 268 241 128
Tax % 27% 27% 28% 27% 23% 26% 26% 25% 25% 25% 25% 26% 25%
89 145 145 128 126 173 173 156 150 198 200 179 97
EPS in Rs 5.73 9.34 9.36 8.25 8.11 11.16 11.15 10.05 9.62 12.68 12.80 11.44 6.01
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1,061 1,144 1,175 1,250 1,501 1,641 1,892 2,190 2,884 3,299 3,723 3,890
868 917 952 1,050 1,209 1,270 1,340 1,681 2,219 2,419 2,705 2,834
Operating Profit 193 226 222 199 292 370 552 509 665 880 1,018 1,056
OPM % 18% 20% 19% 16% 19% 23% 29% 23% 23% 27% 27% 27%
10 55 46 39 37 37 116 39 9 34 35 28
Interest 7 10 5 3 5 3 7 5 34 41 9 5
Depreciation 38 40 46 56 55 65 67 71 112 135 166 177
Profit before tax 159 231 217 179 269 340 594 471 527 738 877 903
Tax % 29% 22% 20% 29% 32% 21% 25% 23% 26% 26% 26% 25%
114 179 173 128 182 268 447 361 389 543 653 674
EPS in Rs 6.70 10.57 10.20 7.66 11.34 17.34 28.92 23.35 25.12 35.01 41.92 41.98
Dividend Payout % 105% 24% 5% 13% 22% 32% 29% 35% 35% 35% 37% 22%
Compounded Sales Growth
10 Years: 13%
5 Years: 16%
3 Years: 10%
TTM: 4%
Compounded Profit Growth
10 Years: 16%
5 Years: 12%
3 Years: 22%
TTM: 10%
Stock Price CAGR
10 Years: 33%
5 Years: 25%
3 Years: 29%
1 Year: 29%
Return on Equity
10 Years: 17%
5 Years: 19%
3 Years: 20%
Last Year: 19%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 17 17 17 17 16 15 15 15 15 16 16 16
Reserves 999 1,206 1,371 1,437 1,469 1,430 1,791 2,088 2,427 2,871 3,362 4,022
105 175 49 28 26 29 39 52 547 359 12 3
327 244 248 285 283 337 355 382 480 668 788 783
Total Liabilities 1,449 1,641 1,684 1,767 1,793 1,811 2,200 2,538 3,470 3,914 4,178 4,824
301 369 609 570 552 583 565 1,204 1,822 1,925 1,883 1,809
CWIP 55 135 4 17 15 16 26 19 55 76 62 61
Investments 598 612 544 567 589 536 811 146 339 531 488 908
495 525 528 613 636 676 799 1,170 1,254 1,381 1,745 2,045
Total Assets 1,449 1,641 1,684 1,767 1,793 1,811 2,200 2,538 3,470 3,914 4,178 4,824

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
143 171 178 116 193 272 335 147 629 789 884 645
-122 -52 -42 -24 -28 24 -231 4 -956 -412 -290 -587
-23 -97 -165 -59 -156 -305 -87 -138 343 -374 -574 -108
Net Cash Flow -2 22 -30 32 9 -10 18 13 16 2 20 -50
Free Cash Flow 73 -18 25 87 152 203 336 -550 -128 532 774 566
CFO/OP 94% 98% 102% 77% 87% 97% 86% 54% 108% 104% 106% 84%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 85 85 82 88 73 77 72 86 66 69 75 67
Inventory Days 109 108 131 134 142 149 163 172 136 152 137 193
Days Payable 53 56 65 76 76 97 96 96 78 109 112 111
Cash Conversion Cycle 141 137 149 145 139 128 139 162 124 112 101 148
Working Capital Days 24 38 80 98 92 82 89 124 81 52 77 197
ROCE % 14% 17% 12% 9% 17% 22% 32% 22% 22% 24% 26% 25%

Insights

In beta
Mar 2011 Mar 2016 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Dec 2025
Medical Representative Productivity (PCPM)
INR Lakhs per month

Log in to view insights

Please log in to see hidden values.

Login
Number of Brands in Top 300 (IPM)
Count
Field Force Strength (Medical Representatives)
Count
Cardiac Therapy Market Rank (IPM)
Rank
India Distribution Locations
Count
Lozenge Manufacturing Global Rank
Rank
Annual New Product Launches (Domestic)
Count
Domestic Formulations Volume Growth
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
53.91% 53.86% 53.83% 53.78% 53.77% 53.74% 53.66% 47.84% 47.73% 47.56% 47.55% 48.80%
9.53% 10.05% 10.35% 11.06% 12.17% 13.63% 14.64% 18.30% 17.77% 15.31% 14.88% 16.33%
18.65% 18.58% 18.53% 18.38% 17.61% 16.81% 16.40% 18.71% 19.62% 22.83% 23.35% 21.38%
0.00% 0.00% 0.00% 0.01% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
17.90% 17.50% 17.27% 16.78% 16.42% 15.80% 15.29% 15.13% 14.87% 14.31% 14.21% 13.48%
No. of Shareholders 55,96560,81763,23063,89266,95362,74362,08163,94870,06471,95769,33874,043

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls